Kimberly Velthuis

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 5

Top Topics

Rheumatoid Arthritis Patients

Combination Therapy

Ejection Fraction

Top Venues

Expert opinion on drug safety

This page only lists publications with an associated author ORCID identifier.

Publications

Kimberly Velthuis, Naomi T Jessurun, Thi D M Nguyen, Joep H G Scholl, Jurriaan R G Jansen, Jette A van Lint, Leanne J Kosse, Peter M Ten Klooster, Harald E Vonkeman
First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanercept. Expert opinion on drug safety (2023)
Kimberly Velthuis, Fenna Poppelaars, Peter M Ten Klooster, Harald E Vonkeman, Naomi T Jessurun
Impact of adverse drug reactions on the treatment pathways of early rheumatoid arthritis patients: a prospective observational cohort study. Expert opinion on drug safety (2023)
Kimberly Velthuis, Fenna Poppelaars, Peter M Ten Klooster, Harald E Vonkeman, Naomi T Jessurun
Impact of adverse drug reactions on the treatment pathways of early rheumatoid arthritis patients: a prospective observational cohort study. Expert opinion on drug safety (2023)
Kimberly Velthuis, Naomi T Jessurun, Thi D M Nguyen, Joep H G Scholl, Jurriaan R G Jansen, Jette A van Lint, Leanne J Kosse, Peter M Ten Klooster, Harald E Vonkeman
First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanercept. Expert opinion on drug safety (2023)
Kimberly Velthuis, Naomi T Jessurun, Thi D M Nguyen, Joep Scholl, Jurriaan R G Jansen, Jette A van Lint, Leanne J Kosse, Peter M Ten Klooster, Harald E Vonkeman
First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanercept. Expert opinion on drug safety (2023)